Latest News & Updates

Breaking News

  • 3 hours ago

  • Pharma Now Editorial Team

Laurus Labs posts 23% revenue rise on CDMO manufacturing scale-up
Breaking News
Ajanta Pharma's 49% US generics surge signals mid-tier scaling shift

Pharma Now Editorial Team

Other trending news you may like to read

Laurus Labs posts 23% revenue rise on CDMO manufacturing scale-up

Laurus Labs reports 23% FY26 revenue growth and Rs 279 crore Q4 profit, driven by CDMO expansion and advanced manufacturing scale-up.

Pharma Now Editorial Team

Pharma Now

Ajanta Pharma's 49% US generics surge signals mid-tier scaling shift

Ajanta Pharma's Q4 FY26 revenue rose 21% to Rs 1,422 crore, with US generics up 49%, a benchmark for mid-tier Indian manufacturers scaling FDA-regulated output.

Pharma Now Editorial Team

Pharma Now

Five FDA observations at Biocon Bengaluru site test biosimilar approval path

FDA issued five procedural observations after a pre-license inspection at Biocon Biologics' Bengaluru site, placing the company's biosimilar BLA timeline under review.

Pharma Now Editorial Team

Pharma Now

SB27 PK data sharpens the pembrolizumab biosimilar race

Samsung Bioepis' SB27 met PK bioequivalence endpoints in a Phase 1 NSCLC study, advancing the pembrolizumab biosimilar programme toward confirmatory trials.

Pharma Now Editorial Team

Pharma Now